Who should not take testosterone replacement therapy?
While TRT has a well-established safety profile for men with confirmed hypogonadism, it is not appropriate for everyone. The American Urological Association (AUA) and the Endocrine Society identify specific conditions where the risks of testosterone therapy outweigh the potential benefits — conditions termed contraindications. These fall into two categories: absolute contraindications (TRT should not be prescribed under any circumstances) and relative contraindications (TRT may be possible with additional monitoring and specialist involvement).
Understanding contraindications protects you from inappropriate treatment and helps you have an informed conversation with your provider. If you have any of the conditions listed below, raise them proactively during your evaluation — don't assume your provider will catch every relevant detail from your history.
What are the absolute contraindications for TRT?
Absolute contraindications mean TRT should not be initiated until the condition is resolved or an alternative treatment is chosen. These are conditions where testosterone poses a clear, unacceptable risk that cannot be adequately mitigated through monitoring.
Active or untreated prostate cancer
Prostate cancer is androgen-sensitive, meaning testosterone can stimulate the growth of existing prostate cancer cells. The Endocrine Society states unequivocally that "testosterone therapy is contraindicated in men with prostate cancer." This applies to active disease, untreated localized cancer, and advanced or metastatic prostate cancer. Men undergoing androgen deprivation therapy (ADT) for prostate cancer should obviously not receive exogenous testosterone, as it directly counteracts the treatment.
Male breast cancer
Though rare (approximately 2,800 cases diagnosed annually in the U.S.), male breast cancer is an absolute contraindication for TRT. Like prostate cancer, breast cancer tissue may be hormone-sensitive. Any history of male breast cancer precludes TRT initiation per current guidelines.
Desire for near-term fertility
Exogenous testosterone suppresses the HPG axis, dramatically reducing or eliminating sperm production in most men. For men who want to conceive within the next 6-12 months, TRT is contraindicated because it acts as an effective (though unreliable) male contraceptive. This suppression is usually reversible after TRT cessation, but recovery takes 6-12+ months and is not guaranteed. The AUA specifically recommends against TRT for men with active fertility goals and recommends alternatives like clomiphene citrate or hCG.
Warning: Testosterone is NOT a reliable contraceptive despite its suppressive effect on sperm production. Some men maintain residual fertility even on TRT. Conversely, TRT cannot be relied upon to preserve fertility. If having children is part of your future plans, discuss this with your provider before starting therapy.
Untreated severe obstructive sleep apnea
Severe obstructive sleep apnea (OSA) that is not being treated is a contraindication because TRT may worsen upper airway collapsibility. The mechanism is not fully understood but appears related to testosterone's effects on neuromuscular control of the pharynx and central respiratory drive. Importantly, once sleep apnea is treated (typically with CPAP), this contraindication is resolved — men on CPAP with controlled OSA can safely receive TRT with monitoring.
Uncontrolled severe heart failure (NYHA Class III-IV)
TRT causes fluid retention through sodium and water reabsorption in the kidneys. For men with compensated, well-managed heart failure, this effect is minor. For men with severe, uncontrolled heart failure (NYHA Class III or IV — symptoms at rest or with minimal exertion), the additional fluid load can exacerbate pulmonary congestion and worsen decompensation. The AUA recommends against TRT in these patients until their heart failure is better controlled.
Hematocrit above 50% at baseline
TRT stimulates erythropoiesis (red blood cell production) through direct effects on bone marrow. Men who already have elevated hematocrit (above 50%) before starting TRT are at higher risk of developing polycythemia (hematocrit above 54%), which increases blood viscosity and the risk of thromboembolic events (stroke, DVT, pulmonary embolism). The underlying cause of elevated hematocrit should be evaluated and addressed before considering TRT.
Summary table: absolute contraindications
| Condition | Why It's Contraindicated | Resolution Path |
|---|---|---|
| Active prostate cancer | Testosterone stimulates prostate cancer growth | Treat cancer first; reassess after remission |
| Male breast cancer | Potential hormone sensitivity of breast tissue | None — generally a permanent contraindication |
| Near-term fertility desire | TRT suppresses spermatogenesis | Use clomiphene or hCG instead; start TRT after conception |
| Untreated severe sleep apnea | TRT may worsen airway obstruction | Start CPAP/treatment; then TRT is permissible |
| Severe heart failure (NYHA III-IV) | Fluid retention worsens decompensation | Optimize heart failure management first |
| Hematocrit above 50% | TRT further raises hematocrit, increasing clot risk | Investigate and correct underlying cause first |
What are the relative contraindications for TRT?
Relative contraindications do not automatically prevent TRT but require additional evaluation, specialist consultation, or enhanced monitoring. In these situations, the risk-benefit analysis must be individualized — TRT may still be appropriate, but the standard monitoring protocol needs to be augmented.
Severe lower urinary tract symptoms (LUTS)
Men with severe LUTS (International Prostate Symptom Score above 19) were historically excluded from TRT due to concerns that testosterone might worsen prostate enlargement and urinary obstruction. Current evidence suggests that TRT at therapeutic doses does not significantly worsen LUTS in most men and may even improve symptoms in some cases. However, starting TRT with severe LUTS warrants urological evaluation and close monitoring.
History of venous thromboembolism (VTE)
Men with a personal history of deep vein thrombosis (DVT) or pulmonary embolism (PE) are at theoretically increased risk because TRT raises hematocrit. The absolute risk increase at therapeutic testosterone levels is debated — the TRAVERSE trial did not find a significant increase in VTE events. However, men with prior VTE (especially those with identified clotting disorders like Factor V Leiden) should be monitored more closely, with hematocrit checked every 3 months rather than every 6 months.
Elevated PSA without urological evaluation
A PSA level above 4.0 ng/mL (or above 3.0 ng/mL in men with risk factors for prostate cancer) should be investigated with urological evaluation before initiating TRT. The elevated PSA may indicate undiagnosed prostate cancer — which would be an absolute contraindication — or benign prostatic hyperplasia, which is a relative one. Once prostate cancer is ruled out, TRT can proceed with regular PSA monitoring.
Uncontrolled hypertension
While controlled blood pressure is not a barrier to TRT, uncontrolled hypertension (consistently above 160/100 mmHg) should be addressed before starting testosterone therapy. TRT's fluid retention effect can modestly increase blood pressure, and adding this to already uncontrolled hypertension increases cardiovascular risk unnecessarily. Stabilize blood pressure first, then initiate TRT with close blood pressure monitoring.
What is the relationship between prostate cancer and TRT?
The relationship between testosterone and prostate cancer has been debated for over 80 years since Charles Huggins demonstrated in 1941 that castration (eliminating testosterone) caused prostate cancer regression. This led to decades of concern that testosterone therapy might cause or accelerate prostate cancer.
Modern evidence has substantially revised this view. The saturation model, proposed by Abraham Morgentaler and colleagues, suggests that prostate tissue androgen receptors become fully saturated at relatively low testosterone levels (approximately 250 ng/dL). Above this threshold, additional testosterone does not stimulate further prostate growth. This explains why large epidemiological studies have not found an association between higher testosterone levels and increased prostate cancer risk.
The TRAVERSE trial did not find a statistically significant increase in prostate cancer incidence in men on TRT gel compared to placebo, though the study was not specifically powered to detect this outcome. Current AUA guidelines maintain that:
- Active prostate cancer remains an absolute contraindication
- TRT does not appear to cause prostate cancer in men without pre-existing disease
- Men with a history of successfully treated, low-risk prostate cancer may be candidates for TRT after an observation period, with urologist co-management
- PSA should be measured at baseline, 3-6 months after starting TRT, and annually thereafter
- A PSA increase greater than 1.4 ng/mL within 12 months of starting TRT warrants urological evaluation
Key takeaway: TRT does not cause prostate cancer based on current evidence, but it can stimulate growth of existing cancer. Baseline PSA screening and regular monitoring are essential safety measures. If you have a personal or family history of prostate cancer, work with a urologist who is experienced in both TRT and prostate cancer management.
Is TRT safe for men with heart disease?
The cardiovascular safety of TRT was a major concern until the TRAVERSE trial provided definitive evidence. Published in the New England Journal of Medicine in 2023, TRAVERSE enrolled 5,246 men aged 45-80 with hypogonadism and pre-existing cardiovascular disease or elevated cardiovascular risk. Over a median follow-up of 33 months, testosterone gel did not increase the incidence of major adverse cardiovascular events (MACE) compared to placebo.
This means that for most men with stable cardiovascular disease, TRT is not contraindicated. The exceptions are:
- Severe uncontrolled heart failure (NYHA III-IV): As discussed above, fluid retention is the concern
- Recent acute cardiac event: Most providers recommend waiting 3-6 months after a heart attack or stroke before initiating TRT, though there is no formal guideline specifying the waiting period
- Uncontrolled hypertension: Stabilize blood pressure first
Men with stable coronary artery disease, controlled hypertension, history of stent placement, or other managed cardiovascular conditions can generally receive TRT safely with appropriate monitoring. The TRAVERSE trial specifically enrolled this population and demonstrated safety.
How does TRT affect fertility?
TRT's effect on fertility is one of the most consequential and often misunderstood aspects of the therapy. Exogenous testosterone suppresses the HPG axis, reducing LH and FSH — the hormones that stimulate sperm production. For most men on TRT, sperm counts drop dramatically, often to azoospermia (zero sperm). A 2005 study found that 65% of men on testosterone became azoospermic within 6 months.
This makes conventional TRT an effective (though FDA-unapproved and unreliable) contraceptive. It also makes it a poor choice for men who want to father children in the near future. The suppression is generally reversible — most studies show spermatogenesis recovery within 6-12 months of TRT cessation — but recovery is not guaranteed, and the timeline varies widely.
Options for men who need both testosterone and fertility
- Clomiphene citrate: A SERM that stimulates endogenous testosterone production while simultaneously maintaining or improving spermatogenesis. It raises both testosterone and sperm count by stimulating pituitary LH and FSH secretion. Typical dose: 25-50 mg daily or every other day.
- hCG monotherapy: Human chorionic gonadotropin mimics LH and directly stimulates testicular testosterone and sperm production. It can raise testosterone to the low-normal range while preserving fertility. Typical dose: 1,500-3,000 IU 2-3x/week.
- hCG co-therapy with TRT: Some providers add hCG to a standard TRT protocol to maintain intratesticular testosterone and spermatogenesis. Evidence for this approach is mixed — some studies show preserved sperm counts, while others show incomplete protection.
- Sperm banking: For men who definitely want TRT but also want future fertility options, cryopreserving sperm before starting testosterone is a reliable insurance policy. Most fertility clinics offer storage for $300-600/year.
- Enclomiphene: The more active isomer of clomiphene, approved in some markets specifically for male hypogonadism. Similar mechanism to clomiphene with potentially fewer side effects. Availability varies.
Warning:If you are under 40 or have any possibility of wanting children in the future, discuss fertility preservation with your provider before starting TRT. Once you've been on testosterone for months, recovering fertility takes significant time and is not guaranteed. This conversation should happen at the first appointment, not after you're already on therapy.
What alternatives exist when TRT is contraindicated?
For men who need testosterone improvement but have a contraindication to conventional TRT, several alternative approaches can raise testosterone levels or address symptoms without the risks associated with exogenous testosterone.
Clomiphene citrate
The most widely used alternative for men with secondary hypogonadism. Clomiphene stimulates endogenous testosterone production through the natural HPG axis, avoiding the testicular suppression and fertility concerns of exogenous testosterone. Studies show it can raise testosterone by 200-400 ng/dL from baseline. Side effects include visual disturbances (rare), mood changes, and elevated estrogen levels. Cost: $10-30/month for generic.
hCG (human chorionic gonadotropin)
hCG directly stimulates Leydig cells in the testes to produce testosterone. It raises testosterone while maintaining spermatogenesis, making it the preferred option for men with fertility concerns. It does not work for primary hypogonadism (where the testes are damaged). The FDA reclassification of compounded hCG in 2020 reduced availability and increased cost. Brand-name Pregnyl/Novarel: $100-300/month.
Lifestyle interventions
For men with mild hypogonadism driven by modifiable factors, lifestyle changes alone can meaningfully improve testosterone levels:
- Weight loss: Losing 10-15% of body weight can increase testosterone by 50-100+ ng/dL in obese men
- Sleep optimization: Ensuring 7-9 hours of quality sleep restores normal diurnal testosterone secretion
- Resistance training: Compound weight training consistently raises testosterone acutely and may improve baseline levels with consistent training
- Stress management: Reducing cortisol removes a major HPG axis suppressor
- Opioid tapering: Chronic opioid use is a known suppressant; reducing or eliminating opioids can restore testosterone
These interventions are most effective for men with total testosterone in the 250-350 ng/dL range whose levels are suppressed by modifiable factors rather than organic disease. They are insufficient for men with severe hypogonadism (below 200 ng/dL) or primary testicular failure. For a complete understanding of TRT and its place in the treatment landscape, return to our TRT 101 pillar guide.
Key takeaway: Having a contraindication to TRT does not mean you have no options. Clomiphene, hCG, and lifestyle interventions can all improve testosterone levels in appropriate candidates. The choice depends on the specific contraindication, your fertility goals, and the underlying cause of hypogonadism. Work with a knowledgeable provider to find the right approach for your situation.
Frequently Asked Questions
Can you take TRT if you have high blood pressure?
Controlled hypertension is not a contraindication for TRT. However, uncontrolled or poorly managed high blood pressure should be stabilized before starting testosterone therapy, as TRT can cause fluid retention that may worsen blood pressure in some men. Your provider should monitor blood pressure at each visit and adjust treatment if needed.
Is TRT safe after prostate cancer?
Active or untreated prostate cancer is an absolute contraindication. However, emerging evidence suggests that TRT may be safe in men with a history of treated, low-risk prostate cancer after an appropriate observation period (typically 1-3 years post-treatment). The AUA acknowledges this shift but recommends shared decision-making with a urologist. This remains an evolving area of research.
Can TRT cause blood clots?
TRT increases hematocrit (red blood cell concentration), which at high levels increases blood viscosity and clot risk. Hematocrit above 54% is the threshold where most providers reduce dose or recommend blood donation. Men with a personal or family history of deep vein thrombosis or pulmonary embolism should discuss the risk with their provider before starting TRT.
Is TRT safe if you have sleep apnea?
Untreated severe obstructive sleep apnea is a contraindication for TRT because testosterone may worsen the condition. However, sleep apnea that is adequately treated with CPAP is not a contraindication. Many men with low T also have sleep apnea — both should be treated. In some cases, treating low T may modestly improve mild sleep apnea through reduced visceral fat.
Can you take TRT if you want to have children in the future?
Desire for near-term fertility (within 6-12 months) is a contraindication for conventional TRT because it suppresses spermatogenesis. Alternatives include clomiphene citrate, which stimulates testosterone and sperm production simultaneously, and hCG, which directly stimulates the testes. Some providers co-prescribe hCG with TRT to preserve fertility, though the evidence for this approach is mixed.